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Abstract
Background: Hedgehog (Hh) signaling, a vital signaling pathway for the development and homeostasis of vertebrate
tissues, is mediated by members of the Gli family of zinc finger transcription factors. Hh signaling increases the
transcriptional activity of Gli proteins, at least in part, by inhibiting their proteolytic processing. Conversely, phosphorylation
by cAMP-dependent protein kinase (PKA) inhibits Gli transcriptional activity by promoting their ubiquitination and
proteolysis. Whether other post-translational modifications contribute to the regulation of Gli protein activity has been
unclear.
Methodology/Principal Findings: Here we provide evidence that all three Gli proteins are targets of small ubiquitin-related
modifier (SUMO)-1 conjugation. Expression of SUMO-1 or the SUMO E3 ligase, Pias1, increased Gli transcriptional activity in
cultured cells. Moreover, PKA activity reduced Gli protein SUMOylation. Strikingly, in the embryonic neural tube, the forced
expression of Pias1 increased Gli activity and induced the ectopic expression of the Gli dependent gene Nkx2.2. Conversely,
a point mutant of Pias1, that lacks ligase activity, blocked the endogenous expression of Nkx2.2.
Conclusions/Significance: Together, these findings provide evidence that Pias1-dependent SUMOylation influences Gli
protein activity and thereby identifies SUMOylation as a post-translational mechanism that regulates the hedgehog
signaling pathway.
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Introduction
The Hedgehog (Hh) family of secreted molecules is crucial
during development and adult homeostasis, regulating diverse
biological processes comprising cell specification and proliferation
(reviewed in [1,2]). Dysregulation of the pathway is implicated in a
range of human diseases that include several congenital syndromes
and common cancers proliferation (reviewed in [3,4]). In
vertebrates, Gli proteins, zinc finger transcription factors, which
are orthologues of Drosophila Ci, mediate Hh signaling [5]. To
date, three Gli proteins, Gli1-3, have been identified. While Gli1
appears to act solely as a transcriptional activator, Gli2 and Gli3
display both transcriptional activator and repressor properties and
Gli3 is considered to function mainly as an antagonist of the
pathway (reviewed in [6,7]). Despite the importance of Hh
signaling, the mechanisms that regulate Gli activity remain to be
fully elucidated. Accumulating evidence suggests that proteolytic
processing by the ubiquitin-proteasome system restrains Gli
activity and/or promotes transcriptional repressor activity [8]. In
the absence of Hh signaling, PKA-dependent phosphorylation of a
cluster of serine residues C-terminal to the zinc finger DNA
binding domain of Gli2 and Gli3 recruits the bTrCP subunit of the
SCF-ubiquitin-ligase complex. Subsequent ubiquitination targets
Gli2 and Gli3 to the proteasome [9,10,11,12]. In the case of Gli2,
this appears to result in its complete degradation [10,13]. By
contrast, Gli3 is partially processed by the proteasome to generate
a C-terminal truncated protein that acts as a transcriptional
repressor [12,14,15,16]. Hh signaling inhibits proteolytic process-
ing of both Gli2 and Gli3 and, as a consequence, these proteins
accumulate [10,15,16]. It is less clear if Hh signaling influences the
activity of Gli1, but it is conceivable that regulated ubiquitination
also plays a role in the post-translational control of Gli1. Whether
additional post-translational mechanisms control the activity of Gli
proteins remains an open question.
Small ubiquitin-related modifier (SUMO) are a family of small
proteins (,10 kDa) with a similar structure to ubiquitin [17,18].
The reversible conjugation of SUMO to lysine residues has been
implicated in the regulation of the activity of several proteins
(reviewed in [18]). Four SUMO paralogs have been described in
mammals (SUMO1-4), of which SUMO1–3 are ubiquitously
expressed, while the expression of SUMO4 is more restricted [19]
(reviewed in [18,20]). The process of protein SUMOylation is
similar to that of ubiquitination requiring Aos1/Uba2 (an E1
activating enzyme) and Ubc9 (an E2 conjugating enzyme) activity.
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specificity and efficiency. Three main subtypes of SUMO E3
ligases have been identified: Pias proteins, RanBP2, and Pc2
[18,20]. However, by contrast to ubiquitination, which tends to
promote degradation of target proteins, the impact of SUMOyla-
tion on proteins is more diverse and less predictable. SUMO
conjugation has been documented to produce changes in cell
location, stability or association with other molecules and SUMO
conjugation to transcription factors has been reported to both
activate and inhibit transcriptional activity (reviewed in [21,22]).
Here we provide evidence that Gli proteins can be SUMOy-
lated. Moreover, the E3 SUMO ligase, Pias1, and SUMO
modification influences the transcriptional activity of Gli proteins.
PKA activity appears to negatively regulate Gli protein SUMOy-
lation. Furthermore, experiments in the embryonic neural tube, a
tissue in which Hh signaling has a well defined and essential role
(reviewed in [23,24]), suggest that SUMOylation of Gli proteins is
required for the activation of a Gli target gene in vivo. Together,
these data identify SUMOylation as a previously overlooked post-
translational modification of Gli proteins that affects transcrip-
tional activity and raises the possibility that regulated SUMOyla-
tion of Gli proteins functions to modulate Gli activity in vivo.
Results
Gli Proteins Are SUMOylated on Specific Lysines In Vivo
In the course of a two-hybrid screen to identify proteins that
interact with Gli3, Pias1- a component of the SUMOylation
pathway - was recovered. We could not confirm this interaction by
co-immunoprecipitation assays (not shown). However, since Pias1
is reported to act as a SUMO E3 ligase [25,26] and enzymatic
interactions may be hard to demonstrate by co-immunoprecipi-
tation, we sought to test whether Gli proteins were SUMOylated
in vivo. Using HEK293 cells, we co-expressed HA-SUMO1 and
either Myc-Gli1, Myc-Gli2 or Myc-Gli3. After 36 h, SUMOylated
proteins were immunoprecipitated and the presence of Gli
proteins in the immunoprecipitated material was assayed by
western blot (Fig 1). In extracts of cells co-transfected with HA-
SUMO1 and Gli1, Gli2 or Gli3, isoforms of the Gli proteins were
detected that migrated slower than predicted by their native
molecular weights. These heavier than expected isoforms were
only present in samples co-transfected with HA-SUMO1 and were
approximately 20–30 kD heavier than the native proteins,
consistent with the reported mobility shift resulting from the
addition of SUMO [20]. Similar results were obtained using
NIH3T3 cells (not shown). We also found that SUMO2 could be
conjugated to Gli1 (not shown). Unfortunately, non-specific
precipitation of Gli proteins was detected in cell extracts incubated
with Protein G beads alone and although various blocking and
extensive washing conditions were tested, none was sufficient to
reliably eliminate the non-specific precipitation. Nevertheless, the
presence of slower migrating bands in each of the extracts from
cells co-transfected with HA-SUMO1 and the Gli proteins suggest
that SUMO1 can be covalently conjugated to the Gli proteins in
vivo.
Comparison of the amino acid sequences of the Gli proteins to
the SUMOylation consensus motif YKXE (where Y is an
aliphatic branched amino acid, and X any amino acid [27],
reviewed in [18]) revealed several potential SUMOylation sites in
each protein (Fig 2A). Two consensus sites were present in Gli1
and conserved through the vertebrate lineage. Three conserved
consensus sites were present in Gli2. The equivalent sites were also
present in Gli3 along with two additional sites (Fig 2A). To
corroborate the SUMOylation of Gli proteins, Gli constructs were
prepared in which specific lysines were replaced with non-
SUMOylatable arginine residues. For these experiments we
focused on Gli1 and Gli3. In Myc-Gli1-2KR both lysine 180
and 815 were mutated to arginine and in Myc-Gli3-5KR lysines
87, 462, 696, 779 and 1422 were substituted with arginine. These
constructs were then assayed for their ability to conjugate HA-
SUMO1 in cells. SUMOylated forms of wild-type Myc-Gli1 and
Myc-Gli3 were readily detected in HEK293 cells expressing HA-
SUMO1. In contrast neither Myc-Gli1-2KR nor Myc-Gli3-5KR
appeared conjugated with SUMO1 (Fig 2B). These data confirm
the SUMOylation of Gli1 and Gli3 and suggest that one or more
of the mutated lysines represent the major SUMOylation sites.
To establish which of the five mutated lysines in Gli3-5KR are
necessary for SUMOylation, we assayed an additional set of Gli3
constructs (Fig 2C). We first examined the SUMOylation of
Gli3A
DN2 and Gli3R, these consist of Gli3 lacking the amino-
terminal and most of the carboxy-terminal domains, respectively.
Both of these constructs were SUMOylated in HEK293 cells
suggesting that both the amino and carboxy domains contain
SUMOylatable residues (Fig 2D). Moreover, multiple slower
migrating bands were apparent upon immunoprecipitation of
Gli3R from SUMO1 transfected cells, compatible with the
possibility that this region contains more than one SUMOylation
site. In contrast to the wild-type versions of Gli3A
DN2 and Gli3R,
the equivalent constructs harbouring lysine to arginine substitutes
in K696, 779 and 1422 (Gli3A
DN2-3KR) and in K87, 462 and 696
(Gli3R-3KR) showed a marked reduction in SUMOylation
(Fig 2D). Immunoprecipitation of Gli3R-3KR revealed a signif-
Figure 1. Gli proteins can be SUMOylated. HEK293 cells were co-transfected with constructs encoding HA-SUMO1 and the indicated Myc-
tagged Gli proteins. After 36 h, cells protein extracts were obtained and co-immunoprecipitation assays were carried out using antibody recognizing
the HA epitope. Then, the co-precipitated material was detected by Western blot using and an anti-Myc antibody (for details see Material and
Methods). Bands with slower electrophoretic mobility than native Gli proteins, correspondening to SUMOylated Gli forms, were detected in the co-
precipitated material (arrows). In many of our experiments non-modified Gli proteins precipitated with the Protein G beads. This non-specific binding
could not be reliably removed in any binding or washing conditions tested. SUMO specific conjugation was therefore analyzed, and confirmed; using
specific lysine to arginine Gli mutated forms (see below).
doi:10.1371/journal.pone.0011996.g001
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bands. This suggests this region of Gli3 may contain one or more
sites in addition K87, K462 and K696 that can be conjugated to
SUMO1, albeit inefficiently. Despite the ability of Gli3R to be
SUMOylated in these assays, it was notable that when
SUMOylation was assayed using full length Gli3 only isoforms
that migrated slower than the full length protein were detectable.
Thus, even though transfection of full length Gli3 generated
significant quantities of processed Gli3, this did not appear to be
SUMOylated in vivo (data not shown). These findings suggest that
full length but not processed Gli3 is a substrate for SUMOylation,
raising the possibility that either the N-terminal of full length Gli3
is not SUMOylated or that SUMOylated Gli3 is not a substrate
for proteolytic processing.
No slower migrating bands were detectable in samples of
Gli3A
DN2-3KR transfected cells. This indicates that K696, 779
and/or K1422 encompass the major SUMOylation sites in the
carboxy-terminal domain of Gli3. We therefore analyzed which
residues in Gli3A
DN2 are required for SUMOylation. Gli3A
DN2DC,
a construct missing the last 205 amino acids of Gli3A
DN2 including
K1422, was still SUMOylated suggesting that this lysine is not
required for SUMOylation in vivo (Fig 2E). This led us to
concentrate on K696 and K779 and analyze their requirement for
the SUMOylation of full length Gli3. We generated two constructs
Gli3K87,462,696R and Gli3K779,1422R. In Gli3K87,462,696R, K87,
K462 and K696 were mutated to arginine while the carboxy
lysines K779 and 1422 were left intact. Gli3K779,1422R had the
reciprocal changes: K779 and K1422 were mutated to arginine
and K87, K462 and K696 were left intact. Immunoprecipitation
of these constructs from HEK293 cells cotransfected with HA-
SUMO1 indicated that Gli3K87,462,696R continued to be SU-
MOylated, however, the amount of SUMOylation was noticeably
Figure 2. Sites of SUMOylation in Gli proteins. A. SUMOylation consensus sites are present in Gli proteins. The diagram shows the position of
the lysine residues where SUMOylation is predicted in human Gli1 (Gli1), mouse Gli2 (Gli2) and human Gli3 (Gli3). B. Co-precipitation assays performed
in HEK293 cells co-transfected with HA-SUMO1 and mutated forms of Myc-tagged Gli1 and Gli3 proteins in which all the predicted SUMOylatable
lysine residues (see above) have been changed to arginine (Gli1-2KR, Gli3-5KR). SUMOylation of these mutated Gli proteins was markedly diminished
or abolished. C. Diagram explaining the structure of the different mutated forms of Gli3 used in Fig. 2D–F. D–F. Co-precipitation assays performed in
HEK293 cells co-transfected with HA-SUMO1 and the Myc-tagged mutated forms of Gli3 indicated in C. Arrows indicate sumoylated forms. D. Both
Gli3 truncated forms, Gli3R (which lacks most of the carboxy-terminal domain of Gli3), and Gli3A
DN2 (which lacks the N-terminal domain) were
SUMOylated in HEK-293 cells. SUMOylation was abolished in Gli3A
DN2-3KR, a form of Gli3A
DN2 where all predicted SUMOylatable lysine residues (see
above) were changed to arginine. By contrast, some SUMOylation was still observed in Gli3R-3KR indicating the existence of SUMOylatable sites in
this region of Gli3 other than those predicted in A. E. The truncated forms of Gli3, Gli3A
DN2 and Gli3A
DN2DC, were SUMOylated in HEK-293 cells. This
suggested that the K1422 residue, which is absent in Gli3A
DN2DC, is not required for the SUMOylation of Gli3A
DN2. F. SUMOylation of the mutant
Gli3K779,1422R was markedly reduced in comparison to Gli3K87,462,696R and wild type Gli3.
doi:10.1371/journal.pone.0011996.g002
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that K779 is likely to be the main site of SUMOylation of Gli3.
Notably this lysine has also been shown to be ubiquitinated by
bTrcp when recruited in response to PKA phosphorylation [12].
PKA Regulates the SUMOylation of Gli2 and Gli3
Previously PKA stimulation has been shown to regulate the
transcriptional activity of Gli2 and Gli3 by inducing the
hyperphosphorylation of Gli2 and Gli3 [10,16]. To determine
whether PKA could also influence the SUMOylation status of
Gli1, Gli2 and Gli3 we performed immunoprecipitations from
cells co-transfected with HA-SUMO1 and an expression vector
encoding a constitutive active PKA. The expression of PKA
appeared to have a relatively minor effect on the SUMOylation
status of Gli1, a change in the proportions of the slower migrating,
SUMO conjugated isoforms, was observed in some experiments,
but SUMOylated forms of Gli1 remained readily detectable
(Fig 3A). Strikingly, however, compared to cells that had not
received the PKA vector, the level of Gli2 and Gli3 SUMOylation
was markedly reduced in the presence of activated PKA (Fig 3A).
The reduction in SUMO1 conjugated forms of Gli2 could not be
accounted for by a decrease in the level of Gli2 protein because the
reduction in SUMOylated form of Gli2 was much greater than
any reduction in the native protein level. Similarly, PKA
stimulation increased the ratio of repressor to full length isoforms
of Gli3 as expected, but the reduction in the level of SUMOylated
Gli3 was much greater than any reduction in Gli3 protein levels.
As noted above there was no evidence that the processed form of
Gli3 was SUMOylated. Moreover, the lack of inhibition of Gli1
SUMOylation suggested that the effect of PKA on the
SUMOylation of Gli2 and Gli3 was specific.
To test whether the regulation of Gli3 SUMOylation by PKA
depends on the direct phosphorylation of Gli3, we took advantage
of a construct, Gli3-PKAM, in which the 6 serines phosphorylated
by PKA are mutated to alanine [16]. Mutation of these sites
completely abrogates the ability of PKA to phosphorylate and
regulate activity of Gli3 [16]. In marked contrast to wild-type Gli3,
PKA did not inhibit the SUMOylation of Gli3-PKAM (Fig 3B).
Indeed, in cells expressing Gli3-PKAM and constitutive active
PKA, larger than expected quantities of SUMOylated Gli3 were
recovered, suggesting that mutation of these serines in Gli3 may
enhance SUMOylation. Together these data provide evidence
that PKA regulates SUMOylation of Gli2 and Gli3. Moreover, the
data argue against an indirect effect of PKA on SUMOylation of
Gli3 and suggest that the amount of SUMO1 conjugated to Gli3 is
inversely related to the phosphorylation of the identified PKA sites
in Gli3.
Pias1 enhances the transcriptional activity of Gli proteins
and is required for the regulation of a Gli target gene
The evidence that Gli proteins can be conjugated by SUMO
prompted us to examine whether the SUMOylation pathway, and
in particular Pias1, affected the transcriptional activity of the Gli
proteins. A consensus binding site has been defined for the Gli
proteins and a reporter (GBS-Luc) consisting of 8 concatemerized
sites provides a reliable assay for Gli transcriptional activity [28].
We first tested the effect of Pias1 on Gli activity in NIH3T3 cells.
Transfection of a Pias1 expression construct resulted in a
significant increase in GBS-Luc activity, suggesting that promoting
SUMOylation is sufficient to augment Gli activity in cells (Fig 4A).
Moreover, Pias1 expression also increased the activity of
transfected Gli1, and Gli2 in NIH3T3 cells. Since Pias1 strongly
affected the transcriptional activity of Gli1, we focused on Gli1 for
the next assays. To determine if the Pias1 effect on Gli proteins
was related to their SUMOylation, we analyzed the effect of a
mutant form of Pias1 lacking its E3 ligase activity, Pias1-C350S
[29,30], on Gli1 transcriptional activity. By contrast with the wild
type form, Pias1-C350S mutant did not affect Gli1 activity (Fig 4B),
indicating that the effect of Pias1 on Gli proteins activity was
dependent on its ability to conjugate SUMO. Furthermore, Pias1
did not modify the activity Gli1-2KR, the version of Gli1 lacking
SUMOylation sites (Fig 4C). Consistent with these data,
transfection of SUMO1 into NIH3T3 increased the activity,
albeit to a lesser extent that Pias1, of Gli1 in NIH3T3 cells
(Fig 4D). Together these data indicate that Pias1/SUMO
conjugation enhance the transcriptional activity of Gli proteins.
To investigate whether Pias1/SUMOylation also influences Gli
activity in tissue that responds to Hh signaling, we turned to the
chick neural tube. We confirmed that SUMO1, PIAS1 and Ubc9
are ubiquitously expressed in the neural tube of chick embryos
(Fig 4E). We first tested whether Pias1 increased Gli activity in
neural cells in vivo. We introduced, by in ovo electroporation,
Pias1, GBS-Luc and normalization plasmids into HH st. 11 neural
tubes and assayed luciferase activity 24 h later. Consistent with the
data from NIH3T3 cells, expression of Pias1 in the neural tube
induced a marked increase in the levels of Gli activity, compared
to controls (Fig 4F). We next assayed the effect of Pias1 on the
expression of the Nkx2.2 homeodomain transcription factor. This
gene is expressed in the ventral neural tube in response to Shh
signaling and its induction depends on a regulatory element that
directly binds Gli proteins [31,32,33]. Consistent with a positive
role for SUMOylation on Gli activity, in ovo electroporation of
Pias1 induced the ectopic expression of the Nkx2.2 throughout the
dorsal ventral axis of the neural tube (Fig 4G). To verify that the
ectopic induction of Nkx2.2 expression by Pias1 was dependent on
endogenous Gli transcriptional activity we took advantage of Gli3-
Znf. This construct consists of only the DNA-binding zinc finger
domain of Gli3, which dominantly blocks endogenous Gli activity,
and consequently inhibits the Shh dependent induction of Nkx2.2
[34]. In ovo expression of Pias1 together with Gli3-Znf, blocked
the ectopic induction of Nkx2.2 expression indicating that the
Pias1 induction of Nkx2.2 is dependent on Gli activity (Fig 4H).
Finally, to verify that the effect of Pias1 on Nkx2.2 expression was
dependent on its E3 SUMO ligase activity, we used Pias1-C350S,
which lacks ligase activity. In ovo electroporation of Pias1-C350S
was not sufficient to induce ectopic Nkx2.2 expression confirming
the Pias1 induction of Nkx2.2 expression depends on SUMO
conjugating activity. Furthermore, expression of Pias1-C350S in
ventral regions of the neural tube, which would normally express
Nkx2.2 in response to Shh signaling, blocked the induction of
endogenous Nkx2.2. This suggests that Pias1-C350S can act as a
dominant negative [30] to inhibit endogenous Pias1 E3 ligase
activity and thereby inhibit Nkx2.2 induction. Together these data
indicate that Pias1, through its SUMO ligase activity enhances Gli
activity in the neural tube and is required for the induction of a
Shh responsive gene.
Discussion
In this report we provide evidence that Gli proteins are targets
of SUMOylation and that Pias1, in a manner dependant on its
ability to conjugate SUMO, affects the transcriptional activity of
Gli proteins in both cultured cells and in embryos. Each of the Gli
proteins has several phylogenetically conserved consensus motifs
for SUMOylation and we provide evidence that SUMO1 can be
conjugated to the lysines in several of these motifs. The addition of
SUMO to Gli proteins appears to boost their transcriptional
activating function and this enhancement appears to be necessary
SUMOylation of Gli Proteins
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Nkx2.2, in the developing neural tube [33,35,36,37]. Consistent
with these data, PKA activity, which negatively regulates Gli2 and
Gli3, appears to block the SUMOylation of Gli2 and Gli3.
Together these data identify SUMOylation as a post-translational
modification of Gli proteins that influences the activity of this
important family of transcription factors.
SUMOylation appears to correlate with, and to increase, the
transcriptional activating function of Gli proteins. SUMOylation
of transcription factors is most frequently associated with
Figure 3. PKA inhibits SUMOylation of Gli2 and Gli3. A. Co-immunoprecipitation assays performed in HEK293 cells co-transfected with HA-
SUMO1, the indicated Glis and constitutively active PKA (PKA). Gli2 and Gli3 proteins were less SUMOylated in the presence of constitutively active
PKA. B. Co-immunoprecipitation assays performed in HEK293 cells co-transfected with HA-SUMO1, constitutively active PKA, and either a wild type
Myc-Gli3 or a mutated form of Myc-Gli3 unable to be phosphorylated by PKA (Gli3-PKAM). Constitutively active PKA did not inhibit the SUMOylation
of Gli3-PKAM.
doi:10.1371/journal.pone.0011996.g003
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previously been shown to increase the activity of several
transcription factors including p53 and Tcf4 (reviewed in [22]).
Our data therefore add to the evidence that SUMOylation can
have positive as well as inhibitory effects of the activity of
transcription factors. Although we have been unable to detect
SUMOylation of endogenous Gli proteins, due to the lack of
appropriate reagents, the evidence supports a model in which
SUMOylation can regulate endogenous Gli activity in a
physiological context. Importantly, SUMO E3 ligase, Pias1,
enhances Gli activity in cultured cells and in embryos and this
appears to be a consequence of its ability to catalyze the covalent
addition of SUMO to Gli proteins (Fig 4). First, a point mutant of
Pias1 that lacks ligase activity does not affect Gli1 activity. Second,
Pias1 does not affect the activity of a form of Gli1 in which the
SUMOylation sites have been mutated to arginine, a residue
incapable of SUMO conjugation. Third, over-expression of
SUMO1 in cells also increases the activity of Gli1. Together
these data favour the idea that direct SUMOylation of a Gli
protein alters its transcriptional activity and argue against models
Figure 4. Pias1/SUMO enhances Gli activity. A–D. Pias1/SUMO enhances Gli activity in cultured cells. Luciferase assays in NIH3T3 cells using
a GBS-firefly luciferase reporter and CMV-renilla luciferase for normalization. cDNAs encoding the indicated proteins and the appropriate empty
vectors – to ensure equal amounts of DNA in each condition – were cotransfected with reporter and normalization plasmids. Firefly and renilla
luciferase activities were assayed after 24 h. The forced expression of Pias1 increased GBS reporter activity (A), particularly in cells co-transfected with
Gli1 or Gli2. By contrast, the forced expression of a mutated form of Pias1 that lacks E3-ligase activity (Pias1-C350S) did not affect Gli1 activity (B).
Consistent with this, the activity of a non-SUMOylatable form of Gli1 (Gli1-2KR) was not affected by the forced expression of Pias1 (C), and the over-
expression of SUMO1 enhanced Gli1 activity although at a lesser extent that Pias1 (D). E. SUMO pathway components are expressed in the developing
chick neural tube. Transverse sections at the thoracic level of chick embryos. The expression of the indicate genes was detected by in situ
hybridization. Sense controls for each probe were used to test specificity. F. Pias1 enhances Gli activity in embryos. In ovo luciferase assay. HH st 11–
12 chick embryos were co-electroporated with the GBS-firefly luciferase reporter and CMV-renilla luciferase normalization plasmid together with Pias1
in pCAGGS vector or an empty pCAGGS vector. The levels of firefly and renilla luciferase were measured 24 h after the electroporation. G–I. Forced
expression of Pias1 induces the ectopic expression of Nkx2.2 in a Gli activity dependent manner. G. HH st chick embryos were electroporated with
pCAGGS-Pias1 and assayed 24 h later by fluorescence confocal microscopy for the expression of the Gli responsive gene Nkx2.2 (red). Electroporated
side is on the right and electroporated cells are indicated by GFP immunofluorescence (green). Ectopic induction of Nkx2.2 was observed in
electroporated cells. H. Co-electroporation of Pias1 with a construct encoding for the zinc finger domain of Gli3 (Myc-Gli3-Znf) (blue), which inhibits
endogenous Gli activity, blocked the ectopic expression of Nkx2.2 (red). I. Electroporation of the mutant Pias1-C350S, which lacks E3-ligase activity,
was unable to induce an ectopic expression of Nk2.2 (red). Moreover, an inhibition of the expression of Nkx2.2 in its endogenous domain was
observed.
doi:10.1371/journal.pone.0011996.g004
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the regulated SUMOylation of other proteins. These data also rule
out the possibility that the effects of Pias1 on Gli proteins are due
to an E3-ligase independent activity of Pias1. Nevertheless, we
have not consistently found an increase in SUMOylation levels of
Gli proteins in cells transfected with Pias1. However, our
experiments relied on the overexpression of tagged SUMO1 and
this might make it difficult to detect any effect of increased Pias1
expression on the SUMOylation. How SUMO conjugation
contributes to an increase of Gli activity remains unresolved.
Although we have not obtained consistent evidence of an increase
in the nuclear localization or stability of Gli proteins in the
presence of Pias1 (data not shown), we cannot rule out the
possibility that changes in the location or stability of a small yet
crucial pool of Gli proteins is responsible for the observed effects.
Moreover, we do not exclude the possibility that other components
of the Hh signaling pathway might also be susceptible to SUMO
regulation. In this regard it is notable that Pias1 has been shown to
interact with Supressor of fused (Sufu) [39], a negative regulator of
the Hh pathway that interacts with Gli proteins [40,41,42,43,44].
It is possible therefore that sumoylation regulates the Hh pathway
at multiple levels.
The mutational analysis of Gli proteins suggest suggests several
lysines are potentially conjugated to SUMO. Whether there is a
hierarchical relationship between these sites and whether an
individual Gli protein harbours multiple SUMOylations is not
known. Moreover, the presence of multiple distinct SUMO
proteins within cells and the potential for some of these forms to
generate polySUMO conjugates [18] raises the possibility that a
‘‘SUMO’’ code exists. This code might result in distinct
combinations SUMO modifications at different sets of lysine
residues of Gli proteins with each combination resulting in a
different effect on the activity of the Gli protein. Further analysis
will be required to determine if different patterns of SUMOylation
are found on different Gli proteins and to resolve whether these
elicit different effects on Gli activity.
PKA is a well established negative regulator of Hh signaling that
directly phosphorylates Gli2 and Gli3 to promote their processing
by the proteasome [10,16]. Our data indicate that PKA activity
also antagonizes SUMOylation of Gli2 and Gli3. We provide
evidence that this antagonism is a consequence of PKA
phosphorylation of Gli proteins (Fig 3A, 3B) and not an indirect
effect of PKA on the SUMOylation or proteasome machinery. It
was also notable that little, if any, SUMO conjugated partially
processed Gli3 protein was observed. Together these data suggest
that PKA dependent processing of Gli proteins and SUMOylation
of Gli proteins are mutually exclusive. In contrast to Gli2 and Gli3,
the SUMOylation of Gli1 was less affected by PKA activity.
Differences in the distance between the PKA phosphorylation sites
and the SUMOylatable lysines in Gli1 and Gli2/3, might account
for this observation. Irrespective of the explanation, the data
further support the contention that the reduced SUMOylation of
Gli2 and Gli3 in the presence of activated PKA is a specific and
direct effect.
As Pias1, like other SUMO pathway components, is expressed
in the developing neural tube (Fig 4E), it is conceivable that it is
capable of regulating the activity of Gli proteins within the neural
tube. Here we provide evidence that Pias1 can increase Gli
transcriptional activity within the neural tube of chick embryos
(Fig 4F). Strikingly, Pias1 can induce ectopic expression of Nkx2.2,
a homeodomain transcription factor (Fig 4G), the activation of
which has been shown to require high levels of Gli activity [35].
Conversely, inhibition of Pias1 activity blocks Nkx2.2 expression.
Taken together, our results suggest a scenario in which Gli
proteins require SUMOylation in order to achieve the highest
levels of activity necessary to induce the most ventral cell identities
within the neural tube.
The finding that Pias1, through SUMOylation, regulates Gli
activity within the neural tube raises the possibility that patterning
throughout the neural tube may be affected by the SUMOylation
machinery. As Pias1 and SUMOylation have been shown to be
involved in the regulation of members of Wnt and BMP pathways
in other systems [45,46] and Wnt and BMP signaling, together
with Shh, play fundamental roles in the control of cell fate
specification and proliferation within the neural tube [47,48,49], it
is possible that Pias/SUMO regulates the intrinsic activity of
proteins that define cell identity, namely members of the
homeodomain and basic helix-loop-helix protein families. The
extent of the role of SUMO conjugation within the neural tube
system remains unknown and will require further investigation.
Materials and Methods
Constructs
Gli constructs were designed using human Gli1 and Gli3 and
mouse Gli2. All Glis were fused to 6X Myc tag at the N terminus
and expressed from the bicistronic expression vector pCAGGS-
IRES-nlsGFP [50]. Gli3-Znf consists of aa 477–645 of hGli3,
Gli3R consists of aa 1–743 of hGli3, Gli3A
DN2 aa 468–1595 of
hGli3 and Gli3A
DN2DC consists of aa 468–1375 of hGli3. All lysine
to arginine mutants were generated using a Stratagene Mutagen-
esis kit according to manufacturer’s instructions. Human Gli3
PKA mutant [16] was provided by from P. Beachy (Howard
Hughes Medical Institute, Maryland, USA). Human Sumo1
(kindly provided by R. Hay) was fused to an N terminal HA tag,
Pias1 and Pias1 C350S mutant have been described [29]. For
electroporation experiments Pias1 and Pias1 C350S were
subcloned in pCAGGS-IRES-nlsGFP vector. Constitutively active
PKA subunit was as described [51].
Cell Culture and Transfection
HEK293 and NIH 3T3 cells were grown in Dulbecco’s
modified Eagle’s medium (GibcoBRL) supplemented with 10%
(vol/vol) fetal calf serum or newborn calf serum, respectively, and
cultured at 37uC in 5% (vol/vol) CO2 in air.
All cells were transiently transfected using Lipofectamine Plus
reagent (Invitrogen) following the manufacturer’s instructions.
Luciferase assay
Luciferase measurements were performed with the Dual-
Luciferase Reporter Assay System (Promega) according to the
manufacturer’s instructions.
Chick in ovo electroporation
All constructs were electroporated into the neural tube of HH st
10–12 [52] chick embryos [53]. After 24 h, embryos were fixed
and processed for immunodetection as described previously [53].
In ovo luciferase assay was performed as previously described [35].
Coimmunoprecipitation
Transfected HEK293 and NIH 3T3 cells were lysed with lysis
buffer (0.15M Tris-HCL, pH6.7, 5% sodium dodecyl sulfate
(SDS), and 30% glycerol) and diluted 1:10 in PBS-0.5% Nonident
P-40 (NP-40) plus complete protease inhibitor (Roche). Cell lysates
were precleared rotating at 4uC for 1 h with prepared Protein G-
Sepharose (Roche). Following removal of preclearing sepharose,
protein extracts were then incubated rotating 4uC for one hour
with 5 ml of mAb anti-Myc antibody 9B11 (Cell Signaling) or 10 ml
SUMOylation of Gli Proteins
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was then added to each sample followed by continued rotation at
4uC for a further 3 h. Beads were then washed four times with
PBS-0.5% NP-40 plus complete protease inhibitor and once with
10 mM Hepes/NaOH pH7.0 followed by addition of 30 mlo f2 x
SDS sample buffer. The immunoprecipitated material was then
fractioned by SDS-PAGE, transferred to a nitrocellulose mem-
brane, and detected by immunoblot with the mAb 9E10 (Santa
Cruz) to detect the Gli myc epitope or the Ab 3F10 to detect the
Sumo HA epitope.
Immunohistochemistry and in situ hybridization
histochemistry
Immunohistochemical localization of proteins was performed as
described [53,54]. mAb mouse Nkx2.2 (74.5A5) antibody came
from Developmental Studies Hybridoma Bank (University of
Iowa). mAb anti-Myc 9B11 was purchased from Cell Signaling.
Sheep GFP antibody (4745–1051) was purchased from Biogenesis.
Images were collected on a Leica TCS SP2 confocal microscope.
In situ hybridization was performed as described [55] using probes
from chick EST clones of Sumo1, Pias1 and Ubc9.
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